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Introduction
Prostate cancer is the most common malignancy in men and is the second leading cause of male cancer related deaths. The multi-step molecular pathogenesis is not clearly defined. Our laboratory has been examining alterations in the interrelated Cdk4/pl6 and pRB pathways. We, and others, have reported that the Cdk4 inhibitor pi6 is commonly induced in primary prostate cancer. As pl6 should be arresting growth it was a surprising finding that it was induced in prostate cancer epithelium. Another gene that is induced in early prostate cancer development is Cdc37. The 50 kDa product of the mammalian cdc37 gene is a co-chaperone protein that preferentially recruits protein kinases and is responsible for their activity (1) (2) (3) . Cdk4 is a wellcharacterized Cdc37 client kinase. We hypothesized that Cdc37 induction may play a positive growth role and counter pi6 induction in prostate cancer. Mechanistically, Cdc37 may bind to and activate more Cdk4 to participate in active cycHn D:Cdk4 complexes, thus negating inactive pl6:Cdk4 complexes.
To test this hypothesis and assess the role of Cdc37 in the progression of prostate cancer, I proposed three Specific Aims or Tasks. These Aims were designed to test the association of pl6 and Cdc37 induction in prostate cancer tissues and, more directly, to assess the role each of these genes could play in normal and cancer prostate cells in vitro. I have outlined the ongoing experiments below point by point, noting progress and issues that remain to be addressed in the following year. Overall, the project has been very successful and has lead to both technological advancements and significant scientific findings. The progress thus far has culminated in a research paper that is currently in peer review and will serve as a basis for an NIH grant submission on June 1. In the coming year I look forward to carrying out the remaining proposed experiments.
Body

Task 1. To examine Cdc3 7 levels in focal regions of primary and metastatic prostate tumors and determine if
they correlate with pi 6 expression.
Rationale: Both pl6 and Cdc37 levels are elevated in primary prostate cancer (4) (5) (6) (7) . If Cdc37, through associafion with Cdk4, is preventing high levels of pl6 fi:om binding Cdk4, then Cdc37 should be upregulated in a ssociation w ith p 16. T hrough analysis o f se rial s ections, i ndividual g lands t hat c ontain h igh 1 evels p 16 should co-express Cdc37. This aim will determine whether or not Cdc37 levels are able to override the effects of pl6 in vivo and examine the prognostic value of the Cdc37:pl6 relationship in early-stage primary prostate cancer.
Previous goals: a. Obtain antibodies to Cdc37 and optimize immunohistochemistry protocols to allow for specific detection of Cdc37 (this has already been accomplished for pi 6). b. Immunohistochemically stain serial sections of 50 primary prostate tumor and normal pairs of tissue for Cdc37 and pi 6.
Progress: Two commercially available antibodies were obtained for Cdc37 detection from Santa Cruz Biotechnology (Santa Cruz, CA). These antibodies have not been verified for immunohistochemical (IHC) techniques. Therefore, through the University of Wisconsin IHC lab these antibodies were tried under various conditions and tissue types. However, no signal was obtained and we concluded that they were uninformative for IHC use. Recently, Santa Cruz Biotechnology has released an anti-Cdc37 antibody certified for IHC applications in paraffin-embedded tissue and this antibody is currently being optimized in prostate tissue.
As an altemafive pl6 and Cdc37 mRNA levels were assessed in laser capture microdissected tissues. Three patient matched tumor/normal tissue pairs were selected. Cryosections were cut, H&E stained, and Gleason score determined by a urologic pathologist. Only matched normal and tumor specimens were used that contained no or all cancer, respectively. Furthermore, only those specimens with moderately differentiated cancer were selected (Gleason score 5-7). To separate epithelium from stromal components, laser capture microscopy was used.
Specimens were cyrosections (10 |im), dehydrated through an ethanol series, and allowed to dry for 3 hours. Epithelium and stromal components were captured using the PixCell II (Acturus, Mountain View, CA) laser capture system. Total RNA was isolated with the RNeasy total RNA isolation kit (Qiagen, Valencia, CA). RNA was precipitated using ethanol and glycogen as a carrier. Each sample was converted into first strand cDNA with Superscript reverse-transcriptase (Invitrogen, Carlsbad, CA). Real time Quantitative RT-PCR was performed by monitoring in real time the increase in fluorescence of the SYBR Green dye as described using a iCycler detection system (Bio-Rad) (8, 9) . For comparison of transcript levels between samples, a standard curve of cycle thresholds for several serial dilutions of a cDNA sample was established. This value was then used to calculate the relative abundance of each gene. These values were then normalized to the relative amounts of 18S cDNA. Quantitative real-time RT-PCR (qRT-PCR) was performed on cDNA generated from each sample. After standardizing to 18S rRNA levels, tumor epithelium consistently expressed more Cdc3 7 message than normal epithelium (2-9 fold; Table 1 ) Therefore, I will be aggressively pursuing the IHC studies from paraffin-embedded tissue using the newly acquired rabbit anti-Cdc37 antibody approved for this technique. If, however the IHC does not work for this specific aim, then western blotting for pl6 and Cdc37 will be performed on tumor and normal prostate tissue extracts. Although this assay dose not demonstrate expression levels in one cell, it will alleviate concerns regarding looking at protein expression and is amenable to high throughput assays.
Task 2. To determine if Cdc37 is able to override pi6 mediated growth arrest.
Rationale: O ur 1 aboratory h as i dentified t hat se veral p rostate c arcinoma c ell 1 ines a re p 16 n egative d ue t o promoter methylation (PPC-1, PC-3 and TSU-PRl) (10) . pl6 re-expression in these cell lines leads to Gi arrest and acquisifion of a senescent-like state (11) . This model provides an excellent system to test this aim since bypassing one factor (pi6) will allow the cells to continue to proliferate. In addition, the relative levels of Cdc37 and pl6 can be controlled. The experiment will be carried out by determining a ratio of Cdk4:pl6 that just restricts growth. Next, either Cdc37 or an empty expression vector will be introduced and the number of cells in S-phase determined. If Cdc37 overexpression is able to raise the number of cells in S-phase over the vector only, then we will conclude that Cdc37 is able to bypass pl6-mediated growth arrest.
was cloned into the pBABE puro expression vector. The Cdk inhibitor, pi6, in the GFP expression vector, pLSG, was as described (12) . The prostate cancer cell line PPC-1 was transfected using Effectene (Qiagen) with various combinations and ratios of these plasmids to determine if Cdc37 could override the growth arrest induced by pi 6. Cell cycle analysis of cells was accomplished by analyzing GFP positive cells pre-incubated with the fluorescent DNA dye Hoechst 33342 (Molecular Probes, Eugene, OR). Cell cycle position of GFP (transfected) cells was determined using MODFIT software (Becton Dickinson, San Jose, CA). Expression of all constructs was determined by western blotting.
The results of this experiment are demonstrated in Table 2 . It was determined that a Cdk4:pl6 ratio of 2:1 was still sufficient to arrest growth, while a ratio of 3:1 began to allow more cells in S-phase. At a Cdk4:pl6 ratio of 2:1, Cdc37 or the empty vector (pBABE puro) were co-transfected. Cdc37, however, was not able to push more cells into S-phase. We therefore conclude that in the PPC-1 cell line Cdc37 cannot overcome pi6 mediated cell cycle arrest. Rationale: Studies demonstrate that Cdc37 can be a positive growth regulator in vivo, causing prostate epithelium hyperplasia, and can act as an oncogene when combined with cyclin Dl or c-myc overexpression in mice (4, 13) . As normal cells progress from proliferation to senescence they accumulate high levels of pi 6 (12) . A necessary alteration for lifespan extension is bypassing pi6 by inactivating pRb, mutating or deleting pi6, or through gene silencing by pl6 promoter methylation (14, 15) . This aim will determine if Cdc37 exerts the observed hyperplastic effects and if Cdc37 can promote immortalization in normal HPECs. 4. Many expressing cell lines have their titer reduced significantly if they are froze down and, therefore, the whole 2-3 month procedure needs to be performed if more supernatant is needed in the future.
As an alternative, Dr. Gary Nolan at Stanford University has devised a vastly improved method for retroviral production. This protocol has been adapted for use in HPECs. Briefly, To generate virus, the DNA vectors were transfected (Effectene, Qiagen) into Phoenix Ampho packaging cell lines (provided by Gary Nolan, Stanford University through ATCC, Manassas, VA) according to the Nolan lab protocol (http://www.stanford.edu/group/nolan/retroviral_svstems/retsvs.html). At day 2 post-transfection, the supernatant w harvested, filtered, 4 )ig/ml polybrene added and placed onto HPECs. After 8 hours, the viral containing supernatan was replaced by F12+. At two days post-infection, HPECs infected with the pBABE puro parent vector were treatec with 4 |ig/ml puromycin. Drug treatment was carried out for three days, at which point no uninfected cells remainec viable. At day 5 post-infection, cells were re-plated to 50-70% confluency. Infection rates for all constructs varied between 5-22%.
This improved retroviral production methodology has allowed vast improvements in: 1. Time: retrovirus is to be produced in 2 days instead of 2-3 months. 2. Retroviral production from all constructs: retrovirus has been made from the negative growth regulator, pi6, and from the apoptosis-inducing construct, Cdc37AC, an impossible feat with standard technologies. ). Ensuing molecular analysis was performed on cellular extracts to gain insights as to mechanistic alterations that were potentially leading to cellular proliferation ( Figure 1 ). Molecular analysis of Cdc37 client pathways indicated enhanced Raf-1 activity, up-regulated Cdk4 and cyclin D2 levels and lower pi6 expression with Cdc37 overexpression. These findings suggest increased Raf-1 and/or Cdk4 activity might underlie the proliferative enhancement ( Figure 1 ).
To address whether loss of Cdc37 function inhibits growth a dominant negative Cdc37 construct, Cdc37AC, was overexpressed in HPECs. This protein retains the ability to bind kinases and homodimerize, however it cannot bind to Hsp90 due to a C-terminal truncation. Thereby, maturation of Cdc37 client polypeptides is blocked (16) . At 4 days post-infection, distinct morphological changes were readily apparent in HPECs expressing Cdc37AC. Cells lost their characteristic cuboidal epithelial morphology, instead becoming contracted, and highly light refractile (Figure 2A ). At 5 days post infection, Hoechst 33342 stained cells were observed by fluorescent microscopy to assess nuclear DNA integrity. An abundance of fragmented, or pycnotic, nuclei suggested the cell death was apoptotic ( Figure 2B ). At the same time point, Cdc37AC and control pBABE puro infected cultures were assayed for proliferation by BrdU incorporation. Effective growth cessation (~10-fold) was caused by Cdc37AC expression with cells accumulating in GO/1 ( Figure 2C ). This data further demonstrates that Cdc37 is critical for proliferation and is necessary for survival.
To further address which of the observed molecular changes could lead to growth enhancement, the Raf-1 induction, Cdk4 and cyclin Dl overexpression were recapitulated. Constitutive Raf-1 activation however resulted in growth arrest ( Figure 3 ). The mechanism behind this growth arrest is unclear, however overexpressed Raf-1 is unable to result in growth activation. Cdk4 was also overexpressed and was unable to generate a proliferative response. Interestingly, cyclin Dl overexpression was sufficient to promote proliferation. These findings are consistent with they hypothesis that Cdc37 mediates growth arrest through inducing Cdk4 activity.
One of the most surprising findings was that blocking Cdc37 activity resulted in apoptosis. This indicates that Cdc37 is necessary for survival. It would also be an important finding that Cdc37 also performs anti-apoptotic functions. Recently, it was demonstrated that Cdc37 is necessary for activity of the anti-apoptotic gene AKT (17) . It is interesting to speculate that Cdc37 overexpression observed in human prostate tissue not only promotes proliferation, but also apoptosis resistance.
Key Accomplishments
• mRNA quantitation of genes using laser capture microdissection and quantitative real-time PCR
• Cloning of all desired cDNA constructs into expression vectors with confirmed gene expression
• Generation of a retrovirus using improved methodology for gene expression in normal human prostate epithehal cells (HPECs)
• Efficient infection and gene expression in HPECs
Reportable Outcomes
A submitted manuscript entitled: Cdc37 Enhances Proliferation and is Necessary for Normal Human
Prostate Epithelial Cell Survival. The manuscript is attached in the appendix.
Conclusions
1. p 16 and Cdc37 mRNA are co-induced in the prostate cancer compared to normal tissue.
2. Cdc37 is not able to overcome pl6-mediated growth arrest in PPC-1 cells.
3. Cdc37 overexpression drives proliferation in HPECs.
4. Cdc37 overexpression results in molecular changes consistent with induction of Cdk4 activity.
5. The Cdc37 downstream Cdc37 target cyclin Dl is sufficient to drive proliferation alone.
6. LossofCdc37 function leads to growth arrest and apoptosis.
Introduction
Cdc37 is a co-chaperone protein that targets and activates multiple protein kinases. These interactions are important for a number of mitogenic signaling pathways.
As a critical component of cell cycle control, the Cdc37dysregulation may be implicated in the development of a number of cancers. Recently, human prostate tissue specimens were surveyed for Cdc37 expression and increased immunoreactivity was found in all specimens analyzed when compared to normal tissues (1). Overexpression of Cdc37 was also found in the prostate cancer precursor lesion, prostatic intraepithelial neoplasia (PIN), indicating Cdc37 may be an important early step in prostate cancer development.
To extend these findings, the targeted overexpression of Cdc37 in mice prostates was performed using a probasin promoter. These tissues displayed significant hyperplasia at In the present study, we examine the role of Cdc37 in the proliferation and survival of genetically intact, non-immortalized epithelial cells in a unique prostate epithelial cell model (23) . Using molecular constructs, the mechanisms through which these signals are ehcited are examined. Consistent with mouse transgenic studies, Cdc37 overexpression in human prostate epithelial cells is sufficient to enhance proliferation.
The mechanism is consistent with an increase in Cdk4 activity. Furthermore, our studies open the possibility that the Cdc37-mediated hyperplastic response in vivo may also arise from resistance to apoptosis. This study supports the hypothesis that Cdc37 is a positive growth regulator, a survival gene, and may play an early role in the progression of human prostate cancer. Figure 2C ). Two antibodies were unable detect the C-terminally truncated Cdc37 levels as their epitopes mapped to the C-terminus. Therefore, RT-PCR was used to amplify a segment of the N-terminus. Modest increases in the N-terminal were found in Cdc37AC infected cells. Presumably, higher cellular Cdc37AC levels led to apoptosis while moderate to low levels resulted in growth arrest ( Figure 2D ). Western analysis demonstrated that the Cdc37 client kinases Raf-1 and Cdk4 expression levels were consistently reduced, indicating the Cdc37AC truncated protein was indeed preventing wild-type Cdc37 activity. Interestingly, wild-type Cdc37 expression was elevated with Cdc37AC expression ( Figure 2D ). This may be explained by a feedback mechanism.
RESULTS
Cdc37 overexpression increases BrdU incorporation in
Another possibility is that overexpressed Cdc37AC binds to majority of the misfolded client kinases, sequestering them from wild-type Cdc37. Without misfolded kinases bound to endogenous Cdc37, it may be less likely targeted for ubiquitination. Thus, the Cdc37 dominant negative construct further demonstrates Cdc37 is critical for proliferation in HPECs and additionally plays a role in survival by preventing apoptosis. To test whether greater Cdk4 activity is capable of increasing proliferation, we overexpressed cyclin Dl in HPECs. Cyclin Dl overexpression is well-established means of increasing Cdk4/6 activity (14, 25, 26) . Following drug selection, infected HPECs were assayed for proliferation by BrdU incorporation. Cyclin Dl generated a marked proliferation induction (51-94% higher; Figure 5A ) leading to both decreases in the GO/1 and G2/M DNA content ( Figure 5B ). Cellular extracts confirmed cyclin Dl overexpression in transfected cells ( Figure 5C ). These experiments indicate that the overexpression of cyclin Dl generates increases in proliferation similar to those found with Cdc37 and that Cdk4 activity is rate limiting.
Raf
DISCUSSION
It is generally accepted that most cancer cells arise from a combination of uncontrolled proliferative cues, as well as, inhibition of cell death pathways. Prostate cancer is no exception. As normal prostate cells transform into high-grade prostatic intraepithelial neoplastic (PIN) lesions, a putative prostate cancer precursor, there is an increase in the number of cells proliferating (27) . Progression to localized prostate cancer involves no further proliferative increases when compared to normal epithelial cells, but a decrease in cell death (27) . One gene induced in early PIN, that is also found to demonstrate high levels of expression in localized prostate cancer, is Cdc37. Cdc37 is critical in several cell growth and death pathways and may have a direct impact on both enhanced proliferation and evasion from apoptosis (6, 9, 11). Our laboratory has a longstanding interest in understanding how genes involved in the Gl cell cycle checkpoint regulate growth in human prostate cells in the progression to cancer. In this manuscript, we examined the role of Cdc37 in the growth of normal human primary prostate epithelial cells in vitro. Our primary finding is that Cdc37 overexpression leads to an increase in the proliferation rate. To our knowledge, the effect of Cdc37 on proliferation in human cells has not been reported. Likely this is due to the use of human normal prostate epithelial cells, as we were unable to demonstrate greater proliferation in prostate cancer cell lines overexpressing Cdc37. Prostate cancer cell lines have been selected for growth in vitro and, therefore exhibit a 2-5 fold higher proliferation rate. We would hypothesize that prostate cancer cells have already upregulated Cdc37 client pathways involved in proliferation. This example study illustrates nicely the utility our HPEC model when investigating early mechanisms of prostate cancer development.
Furthermore, this finding is consistent with the demonstration that targeted Cdc37 overexpression in mouse prostate (PB-Cdc37.1 line) tissues leads to >50% of the prostatic acini developing epithelial hyperplasia and dysplasia (1) . Therefore, the overexpression of Cdc37 has a similar effect in human epithelial cells and is a candidate for the growth dysregulation seen in prostate cancer progression.
A second important observation was that the inhibition of Cdc37 function, utilizing a dominant negative construct, not only halted proliferation, but also efficiently induced apoptosis. Primary HPEC cultures demonstrate greater resistance to the effects of anti-cancer drugs when compared to established, immortalized prostate cancer cell lines (28, 29) . It was remarkable that the degree of nuclear fragmentation seen with the Cdc37AC construct was significantly greater than that which we have observed with Docetaxel, thapsigargin or 5-fluoro-2-deoxy-uracil (data not shown). This finding suggests that not only does Cdc37 function in activating genes involved in proliferation, but also provides an anti-apoptotic role. Therefore it is possible that both higher proliferation rates and apoptosis resistance may lead to the hyperplasia seen in mouse prostate tissues overexpressing Cdc37 (PB-Cdc37.1) and in human prostate cancers (1).
Support for Cdc37 overexpression leading to apoptosis resistance is also demonstrated by recent reports showing that Cdc37 binds to the anti-apoptotic AKT family members (11).
Furthermore, Hsp90 inhibition leads to decreases in steady state AKT levels, as well as a reduction in kinase activity (11) . Since AKT is part of an important survival pathway, reduced AKT activity may sensitize primary HPECs to cell death. Finally, we speculate that prostate cells may be especially responsive to loss of Cdc37 function since the androgen receptor binds to Cdc37 and this interaction is necessary for androgen receptor-mediated transcriptional activity (12) . Future studies will examine if Cdc37 overexpression can also confer apoptosis resistance. Through association with known, and undoubtably other unknown, client kinases, the marmer in which Cdc37 promotes HPEC growth is likely multi-factorial. However, we did find that the induction of proliferation by Cdc37 is consistent with greater Cdk4 activity as Cdk4 levels were upregulated and the Cdk4 inhibitor pi6 was downregulated.
Our analysis of
Unfortunately, due to the low cell number following infection and selection we were unable to directly assay Cdk4 activity using kinase assays. As an alternative, we utilized a phospho-specific pRB antibody directed against the S780 site which cyclin D:Cdk4 phosphorylates during cell cycle progression (32) . However, we found that phosphorylated S780 pRB was dependent only on total pRB expression and was insensitive in monitoring cell cycle progression in these cultures. Experimentally we have also shown that by overexpressing Cdk4 the Gl cell cycle checkpoint could be bypassed, although no change in proliferation was noted. Likely, Cdk4 levels are not rate limiting as has been observed in other primary cells (25) . We overexpressed cyclin Dl, a protein which fiinctions as a Cdk4 binding partner needed for Cdk4 activity, and found higher proliferation could be attained in HPECs. Together, these data are consistent with the hypothesis that Cdc37 expression induces Cdk4 activity, and greater Cdk4 activity can drive proliferation in normal human prostate epithelial cells.
Since the Hsp90/Cdc37 association is important for both proliferation and survival it is a potential target in cancer therapy (33) . hydrocortisone, 1 |ig/ml; human transferrin, 5 fxg/ml; dextrose, 2.7 mg/ml; non-essential amino acids, 0.1 mM; penicillin, 100 units/ml; streptomycin, 100 |ag/ml; L-glutamine, 2 mM; cholera toxin, 10 ng/ml; bovine pituitary extract, 25 ^g/ml and 1% FBS (36) . Cells were passaged using trypsin-EDTA.
MATERIALS AND METHODS
Primary
To generate virus, the DNA vectors were transfected using Effectene consists of the human Raf-1 gene lacking the N-terminal regulatory domain fiised to the human estrogen receptor hormone binding region. The construct has neomycin as a resistance marker and has been previously described (37) . Human Cdk4 and cyclin Dl were PCR amplified from HPEC DNA with Expand proofreading DNA polymerase, sequenced and cloned into pBABE puro.
BrdU labeling and cell cycle analysis-HPECs were labeled with 5-Bromo-2-deoxyuridine (BrdU) (Sigma) for one hour, harvested, and processed using an anti-BrdU monoclonal primary antibody followed by a goat anti-mouse FITC conjugated secondary according to the 
